Oral squamous cell carcinoma cancer stem cells have different drug sensitive to pharmacological NFκB and histone deacetylation inhibition

Nenhuma Miniatura disponível
Citações na Scopus
Tipo de produção
article
Data de publicação
2023
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
E-CENTURY PUBLISHING CORP
Autores
SILVA, Luan Cesar
LEITE, Amanda Almeida
BORGATO, Gabriell Bonifacio
WAGNER, Vivian Petersen
MARTINS, Manoela Domingues
LOUREIRO, Felippe Jose Almeida
LOPES, Marcio Ajudarte
SANTOS-SILVA, Alan Roger
SPERANDIO, Marcelo
Citação
AMERICAN JOURNAL OF CANCER RESEARCH, v.13, n.12, p.6038-6050, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Despite many progresses in the development of new systemic therapies for oral squamous cell carcinoma (OSCC), the five-year survival rate of OSCC is low. The traditional chemotherapies approach (cisplatin - CDDP) shows some limitations like drug toxicity, limited efficacy, and drug resistance. Promising studies suggested OSCC cancer stem cells (CSC) presented resistance to CDDP. We have previously studied many targets, and we extensively showed the efficacy of the NF kappa B signaling and the role of histones acetylation, on different malignant tumors, including adenoid cystic carcinoma and mucoepidermoid carcinoma, but until then the effects of the NFkB inhibitor and histone deacetylase (HDAC) inhibitor on the biology of OSCC were not evaluated. Here we assessed the pharmacological inhibitor of NF kappa B emetine and HDAC inhibitor SAHA on the behavior of CSC derived from OSCC. Our data suggested that CDDP administration resulted in reduced viability of bulk OSCC cells and increased CSC. A single and isolated shot of emetine and SAHA were able to disrupt CSC by inhibiting the NF kappa B pathway and increasing the histone acetylation levels, respectively. Further, the combined administration of emetine and SAHA presented the same CSC disruption as seen in emetine alone.
Palavras-chave
Head and neck tumors, oral squamous cell carcinoma, chemotherapy, target therapy, cancer stem cell
URI
https://observatorio.fm.usp.br/handle/OPI/57914
Referências
  1. Adorno-Cruz V, 2015, CANCER RES, V75, P924, DOI 10.1158/0008-5472.CAN-14-3225
  2. Affolter A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.666515
  3. Akinboye ES, 2017, BIOORGAN MED CHEM, V25, P6707, DOI 10.1016/j.bmc.2017.11.015
  4. Almeida LO, 2016, CANCERS, V8, DOI 10.3390/cancers8010007
  5. Almeida LO, 2014, FEBS OPEN BIO, V4, P96, DOI 10.1016/j.fob.2013.12.003
  6. Aminuddin A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64664-3
  7. Bano N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205518
  8. Borgato GB, 2020, OR SURG OR MED OR PA, V130, P181, DOI 10.1016/j.oooo.2020.05.001
  9. Caudell JJ, 2022, J NATL COMPR CANC NE, V20, P224, DOI 10.6004/jnccn.2022.0016
  10. Chen Z, 1999, CLIN CANCER RES, V5, P1369
  11. Cheng YL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.761379
  12. Dorna D, 2023, J CANCER RES CLIN, V149, P13417, DOI 10.1007/s00432-023-05136-9
  13. Goncalves PH, 2017, ONCOTARGET, V8, P32918, DOI 10.18632/oncotarget.16464
  14. Guimaraes DM, 2016, ONCOTARGET, V7, P42447, DOI 10.18632/oncotarget.9884
  15. Herzog AE, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04268-5
  16. Israël A, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000158
  17. Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.21492, 10.3322/caac.20107]
  18. Jiang P, 2018, CARCINOGENESIS, V39, P252, DOI 10.1093/carcin/bgx138
  19. Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
  20. Komarova NL, 2013, NATURE, V499, P291, DOI 10.1038/499291a
  21. Koyfman SA, 2019, J CLIN ONCOL, V37, P1753, DOI 10.1200/JCO.18.01921
  22. Le John M, 2014, World J Stem Cells, V6, P511, DOI 10.4252/wjsc.v6.i5.511
  23. Li HJ, 2022, J CANCER RES CLIN, V148, P2169, DOI 10.1007/s00432-022-04028-8
  24. Lima DG, 2022, INT J CLIN EXP PATHO, V15, P131
  25. Marques AEM, 2020, J ORAL PATHOL MED, V49, P771, DOI 10.1111/jop.13039
  26. Sebaugh JL, 2011, PHARM STAT, V10, P128, DOI 10.1002/pst.426
  27. Shan F, 2018, ASSAY DRUG DEV TECHN, V16, P27, DOI 10.1089/adt.2017.812
  28. Silva LC, 2023, AM J CANCER RES, V13, P1547
  29. Silva LC, 2022, J ORAL PATHOL MED, V51, P553, DOI 10.1111/jop.13252
  30. Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
  31. Tavares MO, 2022, J ORAL PATHOL MED, V51, P529, DOI 10.1111/jop.13326
  32. Tsuchihashi H, 2020, ONCOL REP, V44, P863, DOI 10.3892/or.2020.7674
  33. Tu SM, 2022, CANCERS, V14, DOI 10.3390/cancers14051338
  34. Uzor PF, 2016, EXCLI J, V15, P323, DOI 10.17179/excli2016-280
  35. Wagner VP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20345-w
  36. Wagner VP, 2016, ONCOTARGET, V7, P73032, DOI 10.18632/oncotarget.12195
  37. Wagner VP, 2018, METHODS MOL BIOL, V1692, P179, DOI 10.1007/978-1-4939-7401-6_16
  38. Webber LP, 2017, HISTOPATHOLOGY, V71, P278, DOI 10.1111/his.13218
  39. Wise-Draper Trisha M, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_350442

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/28